Page 3 - End Results Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BeiGene s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA -February 27, 2024 at 06:02 am EST

Application based on results from global Phase 3 RATIONALE-305 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival in advanced gastric/GEJ cancer Prescription.

United statesUnited kingdomMark lanasaBeigene ltdEnd results programDrug administrationAmerican cancer societyNational cancer instituteEuropean commissionEuropean society for medical oncologyExchange commissionInternational agency for research on cancerBiologics license applicationChief medical officerSolid tumorsEuropean society

Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSherif louisNewsfile corpVenture exchangeNational library of medicineCompany or teloTelo genomics corpRegulation services providerEnd results programMcgill universityJewish general hospitalNational libraryGlobe newswireNorth americaNational institute

Telo Genomics Corp : Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

Telo Genomics Corp : Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSherif louisStefan klotterMcgill universityTelo genomics corpEnd results programRegulation services providerNational library of medicineCompany or teloNewsfile corpVenture exchangeJewish general hospitalNational libraryGlobe newswireNorth americaNational institute

2024-02-13 | TSXV:TELO | Press Release | Telo Genomics Ord Shs

(2024-02-13 | TSXV:TELO) Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients

United statesSherif louisRegulation services providerCompany or teloMcgill universityTelo genomics corpVenture exchangeEnd results programNewsfile corpNational library of medicineJewish general hospitalNational libraryGlobe newswireNorth americaNational instituteNote regarding forward looking

Radical Prostatectomy Not Tied to Worse Sexual Function at 10 Years

Urinary incontinence persisted through 10 years after radical prostatectomy, however. An observational study examined prostate cancer functional outcomes, such as sexual function after radical prostatectomy, at 10 years.

United statesVanderbilt universityDaniela barocasEnd results programVanderbilt university medical centerExpanded prostate cancer index composite